Asimov
PrivateLast Round
Series B
Jan 5, 2023
Total Funding Raised
$204.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Asimov is a biotechnology company that provides mammalian cell engineering software and synthetic biology platforms to accelerate the design and production of biologics and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asimov Comparables
Compare Asimov with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 64x Bio | 84% | |
| ATUM | 79% | |
| Dyno Therapeutics | 77% | |
Asimov Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 5, 2023 | ||||
| Series A | Dec 31, 2019 | ||||
| Seed | Dec 19, 2017 |
Asimov Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Seed |
| CPP Investments | Series B |
| Horizons Ventures | Series B, Series A |
| Fidelity Management & Research Company | Series B |
| Lux Capital | Series B |
| Koch Disruptive Technologies | Series B |
| Pillar VC | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 19, 2026
Launched the RNA Edge System, an AI and synthetic biology platform.
- Mar 17, 2026
Partnered with Score Pharma, Inc. for antibody therapeutics.
Asimov Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Asimov's valuation, stock price, and market status.